Home / Businesswire / Syngenta Announces a New Malaria Insecticide Entering Early Development Phase

Syngenta Announces a New Malaria Insecticide Entering Early Development Phase

BASEL, Switzerland–(BUSINESS WIRE)–Syngenta announced today that a new insecticide active ingredient with a
novel mode of action to address resistance in the control of malaria
vectors is entering the early development phase. The new ingredient,
comes from collaboration between Syngenta and the Innovative Vector
Control Consortium (IVCC) to identify and develop new lead areas of
novel chemistry suitable for the control of vector mosquitoes. Syngenta
and IVCC entered into the collaboration in 2009.

The WHO estimated that in 2016 there were 216 million malaria cases in
over 90 countries around the world. Malaria is responsible for the death
of around 445’000 people each year, and many of those impacted are
smallholder farmers. Research shows that when a smallholder is infected
with malaria during harvest, crop yields fall by almost 50% and income
can drop by 50%.

While yet to be eradicated from many countries, malaria is a preventable
and curable disease. Since 2010, improved prevention and control
measures have led to a significant reduction in malaria mortality rates
globally with success achieved primarily through the use of insecticide
treated bed-nets and indoor residual sprays containing pyrethroid
insecticides. However, these reductions are under threat due increasing
insecticide resistance, reducing the overall effectiveness of vector
control programs

To meet this challenge, Syngenta working with the IVCC brought ACTELLIC®
300CS, a mosquito control solution, to the market. In 2013 it received a
formal recommendation for use by the World Health Organization and it is
estimated that in 2017 this long-lasting control product protected ~34
million people in malaria endemic countries.

Erik Fyrwald, Syngenta CEO said: “With Actellic® 300CS we are
achieving remarkable results, but we are fully aware that new solutions
are required for sustainable vector control. Our joint effort with IVCC
is to discover and develop these solutions which can help to radically
transform public health in regions where people live with the daily
threat of malaria and to eradicate malaria by 2040. ”

About Syngenta

Syngenta is a leading agriculture company helping to improve global food
security by enabling millions of farmers to make better use of available
resources. Through world class science and innovative crop solutions,
our 28,000 people in over 90 countries are working to transform how
crops are grown. We are committed to rescuing land from degradation,
enhancing biodiversity and revitalizing rural communities.

To learn more visit www.syngenta.com
and www.goodgrowthplan.com.
Follow us on Twitter® at www.twitter.com/Syngenta.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be
identified by terminology such as ‘expect’, ‘would’, ‘will’,
‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and
similar expressions. Such statements may be subject to risks and
uncertainties that could cause the actual results to differ materially
from these statements. For Syngenta, such risks and uncertainties
include risks relating to legal proceedings, regulatory approvals, new
product development, increasing competition, customer credit risk,
general economic and market conditions, compliance and remediation,
intellectual property rights, implementation of organizational changes,
impairment of intangible assets, consumer perceptions of genetically
modified crops and organisms or crop protection chemicals, climatic
variations, fluctuations in exchange rates and/or commodity prices,
single source supply arrangements, political uncertainty, natural
disasters, and breaches of data security or other disruptions of
information technology. Syngenta assumes no obligation to update
forward-looking statements to reflect actual results, changed
assumptions or other factors.


Syngenta International AG
Media Office
CH-4002 Basel
+41 61 323 2323
Fax: +41 61 323 2424
Andrew McConville
Switzerland +41 61 323 0618
USA +1 202 737 8913
[email protected]
Andrew McConville
Switzerland +41 61 323 0618
+1 202 737 6521